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Abstract 
Although there have been significant advances in the treatment of visceral leishmaniasis (VL) and 
several novel compounds are currently in pre-clinical and clinical development for this manifestation 
of leishmaniasis, there have been limited advances in drug research and development (R & D) for 
cutaneous leishmaniasis (CL). Here we review the need for new treatments for CL, describe in vitro 
and in vivo assays, models and approaches taken over the past decade to establish a pathway for the 
discovery, and pre-clinical development of new drugs for CL.  These recent advances include novel 
mouse models of infection using bioluminescent Leishmania, the introduction of PK/PD approaches 
to skin infection, and defined pre-clinical candidate profiles.  
 
Abbreviations: Cutaneous leishmaniasis – CL; Mucocutaneous leishmaniasis – MCL; Visceral 
leishmaniasis – VL; Pharmacokinetics PK; target product profile - TPP; target compound profile - TCP;  
diffuse cutaneous Leishmaniasis - DCL; disseminated Leishmaniasis – DL;  Drugs for Neglected 
Diseases initiative – DNDi; area under the curve - AUC; no observed adverse effect - NOAEL; 
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minimum effective dose - MED; oral - PO; intra muscular -  IM; adverse reactions - AR; antimicrobial 
peptides - AMP; oligodeocynucleotides - ODN;  research and development - R & D. 
 
Introduction – Cutaneous Leishmaniasis 
Cutaneous leishmaniasis (CL) is a neglected disease with an estimated global incidence of 600,000-
1,000,000 new cases every year, which mainly affects children in poor areas (Alvar et al., 2012). 
Unlike VL, CL is not life threatening, although it causes disfiguring lesions mostly on exposed body 
parts such as the face, arms, and legs. Hence, affected people are stigmatized and subjected to 
ostracism and, have impaired access to education, marriage, and well-paid jobs, which leads to 
economic losses and psychological damage (Bennis et al., 2018), (Bailey et al., 2019). 
According to the World Health Organization (WHO), CL is endemic in 87 countries around the world, 
predominantly in Afghanistan, Pakistan, the Islamic Republic of Iran, Saudi Arabia, the Syrian Arab 
Republic, Algeria, Ethiopia, Brazil, Colombia, and Peru. The highest proportion of affected countries 
is found in the Eastern Mediterranean region, which suffers political instability, wars and migrant 
movements; followed by the Region of the Americas. Some countries such as Belize, Thailand, and 
the United States have been recently included in the list of endemic territories’ list (“Global 
Leishmaniasis update, 2006–2015: a turning point in Leishmaniasis surveillance.,” 2017).  
CL displays several clinical presentations depending on the Leishmania species, host immunity, and 
transmission. A typical lesion of CL is a painless papule or ulcer at the site where the female sand fly 
feeds. In a variable proportion of cases, it may self-cure within 3-18 months, often developing into 
an ulcer covered with an adherent crust of dried exudate during this period. In the Old World 
countries, CL is mostly caused by L. major, L. aethiopica (zoonotic transmission), and L. tropica 
(anthroponotic transmission). All species are able to produce multiple lesions that tend to heal 
slowly and leave large and disfiguring scars. L. aethiopica can also metastasize to oronasal regions or 
across the whole body skin as diffuse CL. L. infantum usually causes generally single nodular lesions 
that heal slowly but may also affect the oronasal region (Burza et al., 2018). 
In the New World countries, primary lesions may be single or multiple, but lymphadenitis and 
lymphadenopathy are common to lesions caused by species of the Viannia subgenus. In addition, 
secondary cutaneous and mucosal lesions may occur. Parasites spread to the mucous membranes, 
especially those of the nose, mouth, and throat, and cause extensive damage and disfiguration, thus 
giving rise to mucocutaneous Leishmaniasis (MCL). This condition is mainly caused by L. braziliensis 
and L. panamensis/guyanensis (all species of the subgenus Viannia), although it can result from 
infection by other species (Amato et al., 2007). Disseminated Leishmaniasis (DL) is another clinical 
presentation mostly associated with L. braziliensis infections where tens to thousands of 
polymorphic tegumentary lesions develop on several areas of the body (Machado et al., 2019). 
Parasites are present in small numbers in lesions with signs of a strong inflammatory response 
(Machado et al., 2019).  In the New World, another rare but severe form of tegumentary disease is 
diffuse cutaneous Leishmaniasis (DCL) associated mainly with infections by L. amazonensis. DCL is 
anergic, characterized by multiple infiltrated plaques and nodules, and an absence of ulcers or 
mucosal involvement. In addition, DCL is characterized by uncontrolled proliferation of parasites in 
macrophages and an absence of immune infiltration in the lesions (Convit et al., 1972). Cure rates 
for simple CL, without treatment, are dependent on the species; for example, 44% - 72% for L. 
mexicana and 6.2% - 20% for L. braziliensis (Cota et al., 2016). 
 
Cutaneous Leishmaniasis – Current Drugs and Treatments 
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Current treatments for CL have been poorly justified through clinical trials and have sub-optimal 
effectiveness (Gonzalez et al., 2008), (Gonzalez et al., 2009). Treatment has long depended on 
antiquated drugs that are considered far too toxic for introduction under modern registration 
systems.  None of the current systemic therapies, including pentavalent antimonials, miltefosine, 
and amphotericin B used for CL, were conceived or developed as specific treatments for CL. If the 
drug works for VL, then it is tested and adapted for its use in CL populations, despite the fact that 
the pharmacokinetic properties of the drug used to treat a patient with VL are often different to 
those for patients with CL. For example, liposomal amphotericin B, which is effective in most foci of 
VL (except East Africa), displays variable cure rates in CL (Solomon et al., 2013), (Guery et al., 2017). 
 
WHO treatment recommendations for CL are based on the causative species, geographical area, and 
the clinical features of the disease. Recommendations vary from no treatment, mainly for infections 
due to L. mexicana or L. major, to topical or systemic approaches. Local therapies, including 
thermotherapy or cryotherapy with or without local infiltration with antimonials, as well as 
paromomycin ointment, are options with less systemic toxicity but variable efficacy. These methods 
are recommended for subjects with infections due to L. mexicana or L. major, or for patients with 
small and few lesions. Systemic treatments on the other hand, such as miltefosine, pentavalent 
antimonials, pentamidine, or amphotericin B formulations, are recommended for more complicated 
cases, for non-responders to topical treatments, immunosuppressed patients, and for areas where 
progression to mucosal leishmaniasis is prevalent. Miltefosine (Impavido®) was registered with the 
FDA in 2014 for CL infections due to L. braziliensis, L. panamensis, and L. guyanensis. There is not 
much evidence of  miltefosine efficacy against infections caused by Old World species (van Thiel et 
al., 2010), (Lee and Hasbun, 2003), (Velez et al., 2010), (Copeland and Aronson, 2015). Current 
treatments for CL have been reviewed in depth in two recent publications (Aronson, 2017), (Burza et 
al., 2018). Here we focus on the pathway required to discover and develop new treatments for this 
disease.   
 
Cutaneous Leishmaniasis Research Directions, Gaps, and Needs for New Drugs and Treatments 
Over the past decade, there has been significant progress in the treatment and pre-clinical 
development of drugs for VL (Alves et al., 2018), (Van den Kerkhof et al., 2018). In contrast, R & D for 
new drugs and treatments for CL were left behind. There is no coherent “end-to-end” strategy even 
though there have been several new approaches, re-iterations of old ones, and the recent 
identification of new potential drugs and formulations. The one part of the CL R & D pathway that 
has received significant attention is clinical trials and consequently, clear progress has been made. 
Reviews of clinical studies undertaken on drugs and treatments for CL showed the inadequacy of 
most of these studies and the need for a re-consideration of the design and analysis of clinical trials, 
including endpoints (Gonzalez et al., 2008), (Gonzalez et al., 2009). This problem was addressed and 
there is now a clinical methodology to assess new drugs and treatments (Gonzalez et al., 2010), 
(Olliaro et al., 2013), (Olliaro et al., 2018).   
Having established the clinical part of the CL drug development pathway, the essential 
questions for this review are: (i) - do we have any optimised lead compounds, novel chemical 
entities, or re-positioned drugs, novel formulations, or adapted treatments to test in clinical trials? 
and (ii)  if we do, is there an agreed and tested pre-clinical pathway that will effectively advance 
active compounds to candidate drugs? In this review, which in part follows a workshop held at the 
WorldLeish 6 Congress, May 2017, (http://worldleish2017.org/#/), we will focus on the potential 
routes to take new drugs and treatments from discovery to clinical trials. We will examine the 
relevance and use of assays and models for evaluation, the value of PK/PD analysis, systemic and 
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topical formulations, and roles for immunomodulatory compound combinations, and re-purposing 
of drugs. Some of these have previously been presented by the Walter Reed Army Institute of 
Research  (WRAIR)  in a validated, cost effective, gated-tier strategy as a possible approach to CL 
drug discovery using in vitro assays to identify hits which progress to more clinically relevant in vivo 
models (Grogl et al., 2013), (Caridha et al., 2017). 
 
 
Figure 1: WRAIR Cutaneous Leishmaniasis Testing Strategy. Analogs, designed or acquired, are 
assessed for activity (intracellular amastigote) and potential cytotoxicity. All analogs meeting cutoff 
criteria (assigned per case) but with a therapeutic index > 5 are tested for microsomal stability in 
mouse and human microsomes. These higher throughput assays gate the more costly, clinically 
relevant, animal models. In vivo efficacy in mice is initially tested against Old World (L. major) 
parasites, first in a lesion suppression model, then if warranted advanced to the rigorous lesion cure 
model. Initial in vivo experiments use intraperitoneal (IP) route of administration to maximize 
chance of success and provide early dose ranging. If successful, skin and plasma mouse PK is 
performed followed by oral (PO) dosing in the mouse lesion cure model (supporting our TPP).  The 
final tier of in vivo efficacy assesses activity via PO dosing in a second animal species (GSH) as 
required for FDA approval and efficacy against a New World strain of Leishmaniasis in a mouse 
footpad model.  Once late-stage candidates are identified early safety, assessment is performed as 
outlined above. 
 
Product Characteristic Profiles for New Cutaneous Leishmaniasis Treatments  
What sort of drug or treatment do we need and what is the decision pathway for development? A 
clear set of indicators are needed to guide the CL drug R & D process and to ensure decision-making 
points are identified and routes/options for progress defined. These are normally outlined in a 
Target Product Profile (TPP), which is a planning tool that describes the desired R&D outcome and 
enables selection, progression, and management according to well-defined decision matrices. In 
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addition, further parameters are outlined in a pre-clinical Target Candidate Profile (TCP), which is a 
description of the physicochemical, anti-leishmanial, pharmacokinetic, safety, and formulation 
properties of a compound selected for pre-clinical development as a prelude to clinical studies with 
the potential to ultimately meet the TPP.  The Drugs for Neglected Diseases initiative has established 
a TPP and TCP for CL which are shown in Table 1 and 2 (https://www.dndi.org/diseases-
projects/Leishmaniasis/tpp-cl/). 
 
Table 1:  Target Product Profile for New CL Treatments 
ATTRIBUTE TARGET (IDEAL) MINIMALLY ACCEPTABLE 
Target Species All Leishmania species L. tropica or L. braziliensis 
Safety monitoring 
requirement 
None Peripheral Health Centre. No major 
safety concerns. 
Target population Immunocompetent and 
immunosuppressed  
Immunocompetent  
Age / Gender No restrictions > 9 months of age 
Use in pregnancy Yes No 
Tolerability Well tolerated.  All AR’s ≤ grade 1 Systemic AR grade 2-3 in <5%. Local AR ≤ 
grade 2-3 in <30%. No Treatment 
associated mortality 
Contraindications None Females and males of reproductive 
potential  
Efficacy (3M)  >95% patients 60% for L. tropica , 70% for L. braziliensis 
Route of administration  
 Topical / oral  Non-parenteral, or few doses,  if 
parenteral 
Topical ≤14 days 28 days 
Oral  ≤ 7 days  28 days 
Parenteral No 3 injections 
Stability No cold chain, at least 3 years at 
37ºC 
2 years at 4-8ºC 
Cost per treatment  To be defined To be defined 
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Table 2:  Target Candidate Profile (TCP) for New Pre-clinical Candidates for CL Administered by 
Systemic Administration 
ATTRIBUTE ACCEPTABLE 
(OLD WORLD OR NEW WORLD) 
IDEAL 
(OLD WORLD AND NEW WORLD) 
Efficacy 
In vivo: 
 
 
 
In vitro: 
 
>95% reduction in lesion size in mouse 
model with L. tropica OR L. braziliensis (or 
the closest possible representative) 
 
Consistent activity within 10x vs. a panel 
of strains and isolates of L. tropica OR L. 
braziliensis 
In vitro: E
max
 >99%
1
 
 
>95% reduction in lesion size in mouse 
model with L. tropica AND L. braziliensis 
(or the closest possible representative) 
 
Consistent activity within 10x vs. a panel 
of strains and isolates from both New and 
Old World 
In vitro: E
max
 >99% 
Safety 
In vitro: 
 
 
In vivo TI: 
 
No in vitro signals preventing 
development
2 
 
(AUC at NOAEL
3
)/(AUC at MED
95
4
 ) > 10
5
 
 
No in vitro signals preventing 
development  
 
(AUC at NOAEL)/(AUC at MED
95
) > 10 
CMC Synthesis and formulation acceptable to 
enable PO or IM dosing 
Synthesis and formulation acceptable to 
enable PO or IM dosing 
DMPK 
Oral dosing: 
 
 
 
Parenteral 
dosing: 
 
Human dose prediction < 30mg/kg/day 
given QD or BID for a maximum of 28 
days 
 
A maximum of 3 injections over 7 days 
 
Human dose prediction < 30mg/kg/day 
given QD or BID for a maximum of 7 days 
 
 
A maximum of 3 injections over 7 days 
 
Explanatory notes: 
1 Compound able to give in vitro >99% reduction of intracellular amastigotes relative to untreated 
control 
2 Includes: mammalian cytotoxicity, HERG, Ames, micronucleus, broad profiling 
3 Determined in rat repeat dose toxicology for duration ≥ length of treatment in efficacy model 
4 Minimum dose required to achieve >95% reduction in lesion size in vivo 
5 Applies equally to both total AUC and free AUC comparisons. 
 
 
These documents are not “set-in-stone” and can be modified through evidence and relevant 
discussion.  A second point from the TPPs, as outlined by DNDi, is limiting the minimal acceptable 
criteria to “effectiveness against L. tropica and/or L. braziliensis alone” as they are considered to be 
the most difficult to treat. CL is a complex of clinical manifestations with different host-parasite 
interactions (including immune responses) for most species (Scott and Novais, 2016).  Whether there 
should be species specific limitations should be considered with respect to three points:   
• It may be a challenge to find a drug/treatment that works against all forms of CL.  
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• It will be very difficult to afford or attract major partners to develop multiple drugs for CL 
since it has been very difficult to develop one, namely the paromomycin topical formulation 
(Ben Salah et al., 2013), (Grogl et al., 1999).  
• Given the areas of potential use of these species-specific treatments, companion diagnostics 
will also be needed.  
 
In vitro and In vivo Models for Drug Development  
 
Drug development against the Leishmania parasite, a eukaryote organism that survives and 
divides in a low pH inside of a macrophage vacuole in different tissues in the body, can be difficult.  A 
successful drug needs to either kill the parasite in the macrophage or activate the macrophage to do 
the job; whichever, the compound must cross up to 7 membranes and pH changes to reach the 
amastigote with implications for both compound pharmacokinetics and drug targeting (Lamotte et 
al., 2017, Croft, 2017).  Although there has been progress in the development and use of in vitro 
assays and screens, there is no perfect animal model for in vivo testing of potential antileishmanial 
compounds (Figures 1 and 2).  These limitations have contributed to the lack of novel compounds 
that have progressed into clinical development. 
(I) In vitro Assays 
To identify novel chemical entities with activity against those species of Leishmania that 
cause CL, in vitro screens should be based upon assays that: (i) provide active or dividing populations 
of the dividing amastigote, (ii) a measure of drug activity that is readily quantified, both kill and 
preferably rate of kill, (iii) accurately show the activity of standard drugs (ideally two standards per 
assay) at concentrations close to those achievable in serum or tissues (over a long time-course if 
necessary), (iv) use a panel of clinical isolates, as there is known strain/species variation in drug 
susceptibility, (v) ensure that these clinical isolates are of recent origin as there is a defined genetic 
drift in isolates maintained in culture over a long period, and (vi) ensure host cell factors, for 
example type of macrophage used are considered in analysis (Croft et al., 2006), (Bussotti et al., 
2018), (Seifert et al., 2010). In the past, in vitro compound screening has also used promastigotes 
and axenic amastigotes. Promastigotes are grown in large quantities for large screening campaigns 
but targeting the insect stage is not predictive of activity against the clinically relevant amastigote 
stage. Temperature and pH can be altered to derive axenic amastigotes to screen compounds in 
quantities comparable to promastigote screens that demonstrate stage specific differences for 
compounds (Vermeersch et al., 2009). However, the development of imaging and high-content 
screening methods for L. donovani that has come with the advent of reporter transfected parasites, 
has made high throughput screening of intracellular parasites possible and has negated the 
advantage of axenic screens (De Rycker et al., 2013), (Tegazzini et al., 2016), (Siqueira-Neto et al., 
2012). The difference for CL screening to that for VL is the need to test against multiple species. Due 
to the diversity and variability of Leishmania parasites, when using a standardized intracellular 
amastigote assay, lead drug candidates are screened against a panel of Leishmania species from 
geographically diverse areas. In vitro screening against multiple species from different geographic 
regions will not take into account diversity of the host, but can give EC50 diversity data on a larger 
scale than could be achieved in vivo. For example, at WRAIR, potential antileishmanial compounds 
are tested in vitro against luciferase-expressing L. amazonensis, L. major, L. mexicana, L. panamensis, 
L. guyanensis, L. peruviana, and L. tropica. However, even using the best in vitro models, there is a 
large attrition rate of active compounds when moved forward to in vivo models. To make in vitro 
models more predictive, we need more physiologically relevant assays (Zulfiqar et al., 2017). With 
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the advent of organ on a chip technology, a 3D immunocompetent model of human skin is used to 
study drug efficacy on human cutaneous lesions (Horvath et al., 2016). 
(II) In vivo Models 
Confirming the in vivo efficacy of potential antileishmanial compounds that display in vitro 
potency and good chemical characteristics, is one of the most important steps in pre-clinical 
research. Traditional in vivo lesion cure (dorsal and footpad) models using the inbred BALB/c mouse 
and Golden Syrian Hamster (GSH) infected with high inoculums of Leishmania spp. parasites as a 
source of CL  infection, have been widely used for decades to test the efficacy of potential anti-
leishmanial drugs (Mears et al., 2015), (Croft et al., 2006), (Robledo et al., 2012), (Milon et al., 1995), 
(Gomes-Silva et al., 2013), (Gamboa et al., 2008), (Ribeiro-Romao et al., 2014). The highly susceptible 
BALB/c mouse /L. major lesion cure model is highly reproducible, consistent, and has some clinical 
similarities with human CL. Nonetheless, this model is extremely stringent, not likely to detect all 
active antileishmanial compounds and has different pathological features and immunological 
responses compared to human CL (Mears et al., 2015). As a result, this model is less suitable for the 
definitive assessment of antileishmanial drug efficacy (Mears et al., 2015), (Croft et al., 2006). 
Presence of metastatic disease, which leads to death, is a major concern for using the BALB/c 
mouse/Leishmania spp. model in antileishmanial drug discovery (Loeuillet et al., 2016) (Figure 2). In 
general, lesion cure models are invasive, costly, and require a long incubation period before 
observations of drug efficacy can be made. As inflammation and secondary infections can contribute 
to the lesion size, accurate assessment of drug efficacy is also less consistent (Mears et al., 2015), 
(Croft et al., 2006). Use of biopsies with histopathology and polymerase chain reactions (PCR), 
scrapings, cytology brush, and lesion swabs coupled to qPCR offer high sensitivity and specificity and 
are a better indication of the degree of infection compared to using lesion cure as a sole 
experimental endpoint (Croft et al., 2006), (Adams et al., 2014), (Boggild et al., 2011). However, 
some of these methods are invasive and questions remain regarding what part of the lesion 
specimens should be collected from in order to accurately determine parasite load (Suarez et al., 
2015).   
Challenges remain for reproducible, predictive models of L. tropica, L. aethiopica, and L. 
braziliensis. L. braziliensis is particularly hard to mimic in animals since most L. braziliensis strains 
cause self-limited or asymptomatic infections in mice.  Recently, an L. braziliensis strain was shown 
to lead to sustained localized disease in BALB/c mice, allowing for a more robust testing of drug 
efficacy (Coelho et al., 2016).  However, no models of mucosal disease are available yet. 
Furthermore, models need to represent the diversity of immune response in L. braziliensis infections 
that play a fundamental role in the response to therapy as illustrated, for example, by the higher 
treatment failure rate when treatment is initiated very early in the course of the disease, before the 
cutaneous lesions ulcerate (Unger et al., 2009). It appears that early treatment leads to an enhanced 
production of pro-inflammatory cytokines that promote the development of ulcers in spite of 
antimony therapy. This adds another layer of complexity to translating animal model findings into 
clinical data (Costa et al., 2018). 
The most predictive animal models in antileishmanial drug discovery have been conducted 
in inbred mice that self-cure (such as C57BL/6, CBA, and CsS), GSH, and non-human primates (such 
as Syke’s, vervet, baboons, and rhesus macaque monkeys). These models present similar clinical 
symptoms, histopathological features, and lesion cure patterns of human CL lesions that progress to 
ulceration and are followed by complete healing (Mears et al., 2015), (Gomes-Silva et al., 2013), 
(Loeuillet et al., 2016), (Githure et al., 1987), (Freidag et al., 2003), (Amaral et al., 2001), (Flynn et al., 
2005), (Loria-Cervera and Andrade-Narvaez, 2014). Probst et al. have described a natural infection L. 
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major/Rhesus monkey model transmitted by P. papatasi sand-fly bites with high rates of infection 
and an antibody response similar to the human disease  (Probst et al., 2001). Still, non-human 
primate models of leishmaniasis require large amounts of drugs for testing, present ethical 
problems, and as a result, should be used “under the most strict circumstances” as a third tier model 
for confirming antileishmanial drug efficacy before clinical trials begin (Mears et al., 2015). Obtaining 
consistent, non-variant infections in outbred rodent models can be very challenging, which makes 
their use expensive and unpractical (Mears et al., 2015). Females of two sand fly genera, 
Phlebotomus and Lutzomyia, respectively for the Old and New World leishmania parasites, are of 
medical importance as proven vectors of Leishmania species pathogenic for humans (Dostalova and 
Volf, 2012). Sand fly saliva is composed of secreted proteins, and in some cases, nucleosides and 
nucleic acids (Dostalova and Volf, 2012). Salivary proteins have a strong effect on the immune 
system of the host, which includes but is not limited to, inhibition of T cell and macrophage 
activation, diminishing the ability of dentritic cells to present antigens, and reducing neutrophil 
migration during specific antigen-induced inflammation (Abdeladhim et al., 2014). Therefore, 
whenever possible, animal infection should mimic the natural transmission by the sand-fly bite of a 
small inoculum of Leishmania metacyclic promastigotes and saliva in the infection site (Mears et al., 
2015), (Croft et al., 2006), (Abdeladhim et al., 2014),  (Kimblin et al., 2008), (Belkaid et al., 1998), 
(Belkaid et al., 2000), (Cawlfield et al., 2018). Humanized mice models have also been used with 
some success to study the human immune response against the Leishmania pathogen, conduct drug 
discovery studies, and predict possible side effects of new drugs in humans (Wege et al., 2012).  
During the past decade, use of noninvasive in vivo imaging technology has revolutionized 
pre-clinical antileishmanial drug discovery and development by providing a simple, accurate means 
to quantify the Leishmania parasite load in a live host  (Mears et al., 2015), (Croft et al., 2006).  
Several probes such as the firefly luciferase reporter gene (LUC), the green and enhanced green 
fluorescent proteins (GFP and EGFP), mCherry red fluorescent protein (RFP), near-infrared 
fluorescent proteins (iRFP), or a combination of those have been used to monitor the in vivo 
intracellular proliferation of Leishmania spp. parasites (Dube et al., 2009, Gupta and Nishi, 2011), 
(Lecoeur et al., 2010), (Rocha et al., 2013), (Pulido et al., 2012), (Mehta et al., 2008), (Lecoeur et al., 
2007), (Calvo-Alvarez et al., 2012), (Roy et al., 2000), (Millington et al., 2010), (Calvo-Alvarez et al., 
2015), (Filonov et al., 2011), (Bolhassani et al., 2011), (Reimao et al., 2013), (Coelho et al., 2016). Due 
to the strong correlation between the parasite load and fluorescence emission or luciferase activity, 
it is possible to assess Leishmania disease progression and measure drug efficacy without the 
requirement for animal subject sacrifice, which is in accordance with the three R’s (Replacement, 
Reduction, Refinement) of animal testing. Studies have shown that the use of bioluminescent 
parasites to quantify Leishmania spp. infection in the ear is a more accurate approach compared 
with the more traditional measurements of lesion diameter, volume, and thickness (Schuster et al., 
2014). Most recently, Caridha et al. described a new, real time, higher throughput longitudinal in 
vivo imaging BALB/c mouse/luciferase-expressing L. major lesion suppression model that serves as a 
prescreen to measure anti-leishmanial drug efficacy in only 18 days. This model is fast, less costly, 
causes minimal animal pain and suffering, and maximizes the number of potential antileishmanial 
compounds that can be tested, which makes it  a good first tier animal model to assess compound 
efficacy (Caridha et al., 2017) (Figure 1). 
A drug discovery-testing paradigm of cost effective in vitro and in vivo assays and clinically 
relevant in vivo models has proven to be an effective method to screen larger compound collections. 
Furthermore, knowing that physicochemical properties of compounds play a critical role on 
pharmacokinetics as well as compound efficacy, medicinal chemistry studies should be conducted in 
parallel with the efficacy ones. In the gated-tiered strategy described by Caridha et al. and Grogl et 
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al, in order to maximize chances for efficacy, the validated in vitro hits are initially dosed 
intraperitoneally (IP) in the BALB/c mouse/L. major lesion suppression prescreen model as well as 
lesion cure model. During these initial mouse in vivo studies, plasma drug concentrations are 
assessed by drawing 10 µL blood samples extracted from a tail nick (Rahavendran et al., 2012). 
Information gathered at this stage plays a critical role in compound design. Lead compounds are 
later confirmed for oral (PO) efficacy in a second tier BALB/c mouse L. major lesion cure model. At 
WRAIR, efforts are made to avoid, even temporarily, the disseminated disease which makes the 
BALB/c mouse/Leishmania spp. lesion cure model extremely rigorous and might result in the 
“inability to detect potentially useful compounds” (Mears et al., 2015), (Figure 2). Drug treatments in 
efficacy studies in the lesion cure BALB/c mice models start when lesion sizes are ≤ 20 mm2 
compared to previously,  when you had to wait for the average lesion size to be 50 mm2 (Caridha et 
al, 2017). At this stage, full mouse pharmacokinetic analysis is conducted on promising compounds 
to predict oral dosing for follow on studies (Caridha et al., 2017), (Grogl et al., 2013), (Figure 1). In 
the third tier, lead compounds are further tested in a GSH/ L. major lesion cure model (Figure 1). In 
addition, in the third tier models, antileishmanial drug efficacy is assessed against New World 
species such as L. panamensis and L. guyanensis. As mentioned above, testing for antileishmanial 
efficacy against other Old and New World species that cause CL such as L. tropica and L. braziliensis 
is recommended (Mears et al., 2015), (David and Craft, 2009). Of course, the aforementioned issues 
surrounding immune status, stringency, and relevance to human clinical disease merit further 
exploration in order to maximize the predictive value of pre-clinical in vivo testing strategies.  
 
 
Figure 2: Disseminated Leishmania Disease in BALB/c Mice. Mice were infected at the base of the 
tail with 1x10
7
 stationary phase luciferase expressing L. major parasites and the images were 
obtained through three dimensional reconstruction of bioluminescence using DLIT in a BALB/c 
mouse at forty days (image A) and seventy days (image B) post-infection. The brighter, red and 
yellow areas shown in the image are photon intensity measurements representing greater parasite 
counts than the dimmer green-blue areas. Forty days post infections (image A) the L. major parasites 
are visible only in the infected skin at edge of the infection (lesion) site*. At seventy days post 
infections (image B) the L. major parasites are visible in large quantities in both popliteal and axillary 
lymph nodes (PLN, ALN) and possibly in the internal organs.* In our laboratory, using the in vivo 
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imaging technology, the smallest number of parasites that can be visualized in BALB/c mice's skin 
immediately after infection is 1.5x10^4 luciferase-expressing L. major promastigotes. The limit of 
detection for amastigotes in the skin and internal organs has not been determined. Other methods 
can detect presence of parasites in the internal organs at a much earlier time during the disease 
progression.  
 
Pharmacokinetics and Pharmaceutics  
As most candidate drugs  currently in the development pipeline for CL were initially identified as part 
of drug screenings against visceral Leishmania species, several key issues, in addition to species 
variation, in drug susceptibility (ibid) need to be considered (https://www.dndi.org/2018/media-
centre/news-views-stories/news/leish_rdn_status_2018/, accessed on 4-11-2018):  
(i) Drug distribution: As the Leishmania amastigotes are situated in the phagolysosome of 
macrophages located in the dermal layer of the skin at the borders of the lesion close to 
the inflammatory cells, compounds with PK properties for accumulation in visceral 
organs, for example 8–aminoquinolines, might  not be appropriate    
(ii) There are additional options to the systemic treatment required for VL, which include 
topical formulations and local immunotherapy 
(iii) The impact of pathology / immunopathology on drug permeation and distribution in the 
lesion. 
To ensure adequate efficacy against CL, a candidate drug requires delivery at the site of infection 
with optimal exposure, both concentration and time.  A challenge for CL drug R & D is the 
integration of requisite PK and PD parameters into the selection of leads following compound 
screening and testing in vivo models as soon as possible (Figure 3, Table 2). The Lipinski and Dermal 
Rule of five describe certain physicochemical properties that are believed to govern drug 
bioavailability upon oral administration and skin penetration, respectively (Lipinski et al., 2001), 
(Naik et al., 2000). These properties include partition coefficient, molecular weight and H-bond 
donors, and are directly and/or indirectly involved in the administration, distribution, metabolism, 
and excretion processes that play a pivotal role in defining the disposition of a drug. The properties 
can be estimated using software and/or established using an experimental set up. At this stage, they 
should be considered a guideline rather than a go/no-go parameter (McKerrow and Lipinski, 2017). 
Here, we focus on the pharmacokinetics and pharmaceutics of topical drugs, which was the focus of 
the workshop held at the WorldLeish 6 Congress (http://worldleish2017.org/#/).  
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Figure 3. A Drug discovery progression pathway for CL including the evaluation of both 
pharmacokinetic and pharmacodynamic parameters. 
 
Topical therapy is warranted for management of patients with few, localized, and uncomplicated 
lesion caused by Old and New World CL (WHO, Technical Report Series 949, 2010), (Blum et al., 
2014), (Aronson, 2017).The skin is typically a peripheral compartment for drug distribution that can 
be reached either through systemic drug exposure whereby the drug is taken up in the blood stream 
and carried to the parasite-containing lesion skin via skin capillaries or, topically via penetration into 
the skin and lesion by a series of partitioning and diffusion steps. In the ideal scenario where CL 
lesions are diagnosed early and treated during the papule or nodular stage, a potent topical 
antileishmanial drug would show efficacy by penetrating all skin layers, targeting only the parasite-
containing parts of the lesion, and avoiding uptake in the systemic circulation. In reality, the majority 
of CL patients present with open lesions which lack the epidermis and stratum corneum. Even if the 
epidermis is present, it is crusty and highly modified (Karram et al., 2012), (Figure 4). Depending on 
the physicochemical properties of the drug, especially the ability to permeate through skin layers, 
removal of the crust and application of a dressing could be considered in some cases. A major 
drawback to both “drug-like” guidelines is that they do not take into account how the pathology 
affects drug delivery to the target tissue in ulcerated CL lesions and/or modified epidermis including 
the stratum corneum on nodular lesions of CL. For the topical rule of five, these physicochemical 
indicators were obtained by modelling skin permeation as a series of diffusion and partition 
processes across the stratum corneum as the main permeation barrier. As mentioned above, they do 
not take into account the inflammation of the dermis and/or thickening of the epidermis, both of 
which are known to impact topical application (Wijnant et al., 2018), (Maleki et al., 2017). 
Furthermore, CL patients often present with multiple lesions at varying stages of progression (Figure 
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4). During the early stages, the epidermis is still present; however, little is known about the barrier 
capacity of the stratum corneum. In the ulcer stage, dermal skin layers are exposed and the 
epidermis is absent. Even though the crust is almost constantly removed in a couple days by  cream 
applications under a dressing, during the later healing stages, there is crust formation which might 
complicate topical drug delivery (Karram et al., 2012). 
 
 
 
Figure 4: A schematic representation of the skin at different stages of CL. An early form of CL is 
shown in (A) where the skin is visibly still intact but a small nodule or papule is visible; (B) shows the 
more advanced stage whereby the crust was removed and an ulcer is exposed. The epidermal layers 
of the skin (including the stratum corneum) are absent. As part of the healing process, a crust is 
formed (C). 
 
In experiences with topical paromomycin applied daily for 20 days, patients suffering from 
simultaneous ulcerated and nodular lesions cured of all lesions regardless of their aspect at the time 
of starting therapy (Ben Salah et al., 2014). These practical considerations may simplify the 
applicability of topical treatment with creams, despite otherwise important theoretical concerns. 
Further evaluation of DMPK parameters such as compound stability (using whole hepatocytes and 
microsomes) and intrinsic permeability (using caco-2 and/or MDCK-MDR1 cell lines) are currently 
standard practice in the pharmaceutical industry. The former assays are especially important for 
orally administered drugs that are absorbed through the gut membrane and undergo first-pass 
metabolism in the liver before reaching systemic circulation. Esterases and CYP enzymes are also 
present in the skin and therefore might contribute to drug metabolism and excretion, even though 
drug metabolism in the skin is believed to occur to a far lesser extent than orally administered drugs 
(Baron et al., 2008). In an attempt to evaluate and identify ‘red flags’ for skin drug stability, 
candidate drugs are incubated in skin homogenate. The reduction of the parent compound fractions 
left at the end of the assay are then compared to the fractions of paraben drugs that are known 
substrates of skin esterases (Van Bocxlaer et al., 2018). Caco-2 and MDCKII-hMDR1 permeability 
assays are used to classify the level of permeation of test compounds crossing the gut and the blood-
brain barrier (Figure 5). It also allows identification of drugs that are substrates for the P-
glycoprotein efflux transporter as it potentially reduces the bioavailability of the drugs and could 
lead to a reduced ability to penetrate into macrophages. The evaluation of binding is important as 
only the unbound drug fraction is able to exert activity and thus a low bound fraction would appear 
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desirable. On the other hand, low drug binding to skin components is thought to reduce residence 
time of the drug in the skin and enhances uptake in and excretion via the lymphatic system. Some 
evidence suggests that minimal levels of binding to skin components is desirable and is indicative of 
topical drug activity. However, this work is limited to one chemical series and further studies would 
have to be conducted to verify this hypothesis (Van Bocxlaer et al., 2018). In addition, normal skin 
components may be different from lesion skin components. One pilot study has analysed the 
evolution of parasite loads in patients with ulcerative lesions treated with topical paromomycin 
applied under semi-occlusive dressings, and showed similar efficacy in superficial and deep layers of 
lesions (Ben Salah et al., 2014). 
Despite their shortcomings, the available in vitro and in vivo CL models allow for discrimination and 
progression of the most promising compounds based on their skin penetration and disposition 
properties. As mentioned above, in the majority of CL cases in the field, the epidermis is not present 
and the real issue is not drug permeation of the initial skin layers but obtaining drug retention in the 
dermis to exert maximal antileishmanial parasite killing. In this context, drug disposition studies are 
important to determine which drugs penetrate and remains in the skin, whereas permeation studies 
can help to identify which factors thrive the process (i.e. diffusion or partition processes) which is 
important for formulation purposes. Drug penetration and disposition into the skin can be evaluated 
using a number of membranes depending on the assay hypothesis or the intended usage of the end 
product. Reconstructed human skin is commercially available in a 24-well plate system and requires 
limited set-up and equipment. This user-friendly format is therefore an attractive alternative to 
costly and difficult-to-obtain human skin and equally allows predictive evaluation of percutaneous 
permeation (Schafer-Korting et al., 2008). On the other hand, mouse skin that is less predictive of 
drug permeation through human skin due to physical skin differences, offers the advantage to 
correlate the results of permeation through a CL lesion to in vivo efficacy in the CL mouse model. 
Whilst a permeation flux similar or higher than the model skin permeants caffeine and testosterone 
indicates adequate permeation across the stratum corneum, also considered the main barrier to skin 
permeation, some retention of the drug into the skin has shown to be beneficial for topically applied 
drug efficacy (Van Bocxlaer et al., 2018).  More importantly, the drug disposition in different skin 
layers can be evaluated at the end of the experiment by removing and retrieving the drug left on the 
skin from the epidermal layers by tape stripping and extracting the drug from the lower dermal 
layers to evaluate the amount retained in the skin.  
To further complicate matters, a drug is rarely administered as the active pharmaceutical ingredient 
only. Instead, it is incorporated in a suitable carrier system composed of excipients including 
solvents and penetration enhancers. Some of these individual components and/or their 
combinations have been reported to influence the permeation of the active drug into the skin. It is 
therefore important to evaluate the percutaneous drug penetration ideally using uninfected and 
infected skin in the before mentioned Franz diffusion cell type assays (Figure 5). Whilst being a 
helpful tool, the reproducibility of these assays can be variable. To this respect, study design, skin 
type used, donor and receptor medium, and experimental set up should be carefully considered 
(Henning et al., 2009).  
Encapsulation of drugs is another useful pharmaceutical strategy for topical CL treatment as it can 
offer enhanced permeation of the active drug, immunomodulatory effects, and macrophage-
targeted delivery (Moreno et al., 2014), (Parra et al., 2018). Considering the complex cellular and 
tissue interactions of these particles, the evaluation of skin penetration requires extensive model 
optimization and combinations of sensitive imaging and detection methods such as Raman 
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spectroscopy, X-ray microscopy, and flow cytometry in addition to the Franz diffusion cell assays 
(Vogt et al., 2014).  
 
 
 
Figure 5. A schematic representation of a permeation assay using a 24-well plate system (A) or a 
Franz diffusion cell (b) 
 
Models for Immunomodulators   
 
Immunotherapy is an alternative approach to the treatment of CL patients, particularly for those 
who cannot use pentavalent antimonials such as patients with nephropathy or cardiopathy. Cost and 
applicability have been major issues for real-life use in CL, but progress in this field may give rise to 
very short courses (ex. one or two injections of long-lived antibodies) at reduced costs. A recent 
review has detailed the immunotherapeutic approaches, including therapy with antibodies, 
cytokines, and vaccines (Taslimi et al., 2018). In clinical studies, immunotherapeutics have been used 
successfully in combinations with interferon-γ as well as small molecules and standard anti-
leishmanial compounds (Dalton and Kaye, 2010), (Convit et al., 2003), (Sundar et al., 1994), (Taslimi 
et al., 2018). However, efficacy has not been constant and at least 2 controlled studies have shown 
no effect of interferon, and several studies using imiquimod in CL have shown no or marginal 
superiority over reference treatments (Harms et al., 1991), (Arana et al., 1994), (Firooz et al., 2006), 
(Miranda-Verastegui et al., 2009). Progress in this field would require a better understanding of 
immune mechanisms of immunopathology and spontaneous cure in each major form of human CL. 
Relatively simple paradigms raised in mouse models may not yet deconvolute  the full complexity of 
human CL. 
For CL species, both small and large molecule immunomodulators have been studied in vitro using 
various macrophage models, alone and in combinations (Zahedifard and Rafati, 2018). Of the 
macrophage models available, bone-marrow derived macrophages have proved to be most useful as 
they (i) represent a more homogenous population of cells than peritoneal exudate cells or monocyte 
derived cell lines, (ii) show full range of responses to stimulation compared to cell lines, and (iii) 
significantly higher phagosomal functions such as acidification and proteolysis in compared to cell 
lines (Guo et al., 2015).  For in vivo studies, both BALB/c and C57BL/6 mice have been used as 
experimental models. For CL, the BALB/c mice are the most widely used. Inbred mouse models have 
the advantage of (i) reproducibility, (ii) identification of precise mechanism of action as the immune 
pathways have been well-defined, (iii) faster readout, and (iv) more accessible reagents for any 
manipulation to show the proof of concept. At the same time, caution has to be exerted over the 
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interpretation of data from rodent model studies and translation to human use, as there are defined 
phylogenic and immunopathology differences, in particular TLR and NLR gene repertoire differences 
influence their function (Ariffin and Sweet, 2013).    
 
Recent studies illustrate the use of animal models in the development of compounds with 
immunomodulatory properties. Antimicrobial peptides (AMPs) can induce tissues and specific cells 
to regulate gene expression and secretion of cytokines and chemokines, wound healing, as well as 
anti or pro inflammatory effects, with activity against different species of Leishmania both in vitro as 
well as animal models (Abdossamadi et al., 2016). In addition, oligodeoxynucleotides (ODN’s) 
containing unmethylated  CpG motifs which mimic microbial DNA and are recognized by toll-like 
receptor (TLR) 9, trigger B cell activation and cytokine production as well as stimulate maturation 
and activation of plasmacytoid dendritic cells and production of pro-inflammatory cytokines such as 
IFN-γ and IL-12, (similar to mouse model) (Verthelyi et al., 2002).  These properties make them 
useful, amongst others, for treatment of infectious diseases (Leifer et al., 2003).  Intradermal (ID) 
administration of CPG ODN type D/A at the site of L. major infections, respectively 3 days before and 
3 days after and 10 days after infection with 1x107 metacyclic promastigotes, reduced the severity of 
L. major caused lesions in rhesus macaque monkeys (Flynn et al., 2005).  In the same study, a single 
treatment dose of CPG ODN administered systemically (sub cutaneous) two weeks post infection 
with 2x106 metacyclic L. major parasites significantly reduced lesion size in rhesus macaque monkeys 
(Flynn et al., 2005). In a study conducted in 2002, co-administration of CpG ODN with non-viable L. 
amazonensis parasites provided significantly increased protection in rhesus macaque monkeys 
infected ID with L. major parasites compared to the control group (Verthelyi et al., 2002). A range of 
small molecules, for example, a cream of the TLR-4 agonist imiquimod (an imidazoquinoline), is 
active in vivo in L. major infected BALB/c mice (Buates and Matlashewski, 1999). In a novel ex vivo 
model, the presence of immunomodulators CpG and pentoxifylline modified the host immune 
response and affected the paracidicidal activity of meglumine antimoniate and miltefosine, such“ 
underscoring the importance of pre-clinical evaluation of immunotherapeutic strategies” (Gonzalez-
Fajardo et al., 2015). 
 
Conclusion 
Since the last review of the CL drug R & D pathway (Modabber et al., 2007), no new effective and 
widely applicable drug or procedure has been developed for the treatment of CL (Modabber et al., 
2007). Recommendations have been modified to reduce the proportion of patients receiving 
potentially toxic systemic drugs which are often administered without proper medical supervision in 
endemic areas (WHO 2010, WHO Manual for Case management East Mediterranean WHO region 
2014). Local treatment has been shown to be applicable in a majority of patients and endorsed by 
experts (Morizot et al., 2013), (Blum et al., 2014), (Aronson, 2017). An aminoglycoside-containing 
cream has been developed through a collaborative effort funded by WRAIR, but its effectiveness, 
safety, and ease-of-use have not yet translated into wide availability. A painless local procedure is a 
better treatment for CL than painful physical methods like cryo-or thermo-therapy requiring tools 
and expertise and which proved unsustainable in real-life conditions, justifying the search for new 
topical options. However, any local therapy will have limitations. Some lesions, like the periorificial 
ones, are difficult to treat locally, even with a cream. The treatment of multi-lesional or 
disseminated forms such as PKDL as well as the prevention of metastatic MCL, can be better reached 
with a short oral course of an effective drug. Strong candidates, some of which show oral activity in 
mouse models, are in the pipeline and we are moving towards the pre-clinical pathway and criteria 
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to determine the best way to select those with the greatest chance of success in patients (Van 
Bocxlaer et al., 2019). Pre-clinical tools to assess safety and efficacy of antileishmanial agents have 
shown great progress over the last two decades. Their optimal use will accelerate the delivery of 
satisfactory treatment options for neglected patients with CL.  
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